The 99th edition of the HPRA Drug Safety Newsletter includes information on the following medicines:

• Erythromycin – Updated warnings regarding cardiovascular risks and infantile hypertrophic pyloric stenosis
• Vascular Endothelial Growth Factor (VEGF) pathway inhibitors – Risk of aneurysm and artery dissection
• Implanon NXT (etonogestrel implant) – Updated insertion and removal instructions due to risk of neurovascular injury and implant migration
• Insulin-containing medicines – Risk of cutaneous amyloidosis and potential for associated changes in glycaemic control
• Leuprorelin-containing depot medicines – Risk of lack of efficacy due to incorrect reconstitution and administration
• Xeljanz ▼(tofacitinib) – Updated recommendations due to increased risk of venous thromboembolism and serious and fatal infections
• Risk of respiratory depression and sedation associated with Epaclob 1mg/ml and 2mg/ml oral suspension (clobazam)

For further details please visit the HPRA website.